Delivery Order 75N95022D00012-75N95024F00001
Award Date 6/1/24
Potential Completion Date 4/30/25
Potential Value $858K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Austria
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award to Scantox Neuro GMBH, a for-profit organization based in Austria, is for $249,000.00 to conduct tolerability studies of candidate Alzheimer's disease (AD) drugs and evaluate the efficacy of poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic AD mouse model. The award is part of the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments Identified by Multi-Omics Analyses...
- This is a $199,812 firm fixed price purchase order awarded by the National Institutes of Health's (NIH) National Institute on Aging (NIA) to QPS Austria GMBH, a contract research organization. The contract is for in vivo efficacy studies of a candidate Alzheimer's treatment in a transgenic mouse model. This award is part of the NIA's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which aims to identify FDA-approved drugs that may be repurposed as disease-modifying...
- The Department of Health and Human Services' National Institutes of Health National Institute on Aging has awarded a $830,053.00 firm fixed price delivery order contract to QPS Austria GMBH, a contract research organization, to conduct experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This delivery order is part of a larger indefinite delivery contract with QPS Austria GMBH to provide these services, with a potential total value...
- <p>The National Institutes of Health National Institute on Aging, within the Department of Health and Human Services, awarded a $638,000 firm fixed price delivery order contract to QPS Austria GmbH. The contract is for experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. The period of performance is from June 1, 2022 through May 31, 2023, with all work to be conducted in Austria by QPS Austria GmbH as the prime contractor.</p>
- The Department of Health and Human Services' National Institutes of Health National Institute on Aging awarded a $298,624 firm fixed-price purchase order to QPS Austria GmbH to provide phenotypic screening services to identify effective treatments for Alzheimer's disease. The requirement, as outlined in the solicitation, is for the contractor to test approximately 20 FDA-approved drugs that have been nominated as potential treatments in order to determine if exposure is associated with lower...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to the National University of Singapore. The $169,830 contract is for testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity. This is part of the NIH's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which is testing approximately 20 FDA-approved drugs to...
- This is a firm-fixed-price purchase order award to Alamar Biosciences, Inc. by the National Institute on Aging (NIA), a civilian agency, for $247,000.00. The contract is for providing proteomic analysis services, including the NULISAseq CNS Disease Panel 120 assay, next-generation sequencing, and bioinformatic support for 1,118 plasma samples. The purpose is to identify biomarkers that can be used to classify and stage Alzheimer's disease. This award is not associated with a set-aside and is the...
- <p>The National Institutes of Health Office of Logistics and Acquisition Operations awarded a $1,499,309 delivery order contract to the National Academy of Sciences for priority-setting for prevention and treatment-related research on Alzheimer's disease and related dementias at the National Institutes of Health. The contract is cost-no-fee and will be performed in Washington, D.C. over a period of approximately two years, from March 2023 through March 2025.</p>
- This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), to Curia Global Inc. (doing business as Amri) for the non-GMP synthesis of up to 100 compounds in 2-10 milligram quantities. The purpose is to identify molecules that bind the KIAA0203 protein, which could potentially lead to the development of a new Alzheimer's drug. The contract has a period of performance from...
- The National Institute on Drug Abuse awarded a $45,881.30 firm fixed-price purchase order to Biocrates Life Sciences AG, an Austrian-based metabolomics company, on September 4, 2020, for research supporting the study "Brain and Blood Bile Acid Concentrations in Cognitive Aging and Alzheimer's Disease." The contract was completed by September 29, 2021, and was not subject to any set-aside designation. Biocrates specializes in metabolomics technologies and quantitative laboratory...